Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...

Building on the success of the anti-Myostatin program, iBio Launches New Program Featuring Myostatin + Activin A Bispecific ...

Explore how immuno-oncology drugs are transforming cancer treatment and discover the rising trend of anti-obesity drugs in ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

1 Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, The Netherlands Objectives Millions of patients worldwide are treated with therapeutic ...

Copyright held by the owner/author(s).

Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, ...

The firms will work together to create a bispecific antibody with two anti-cancer payloads and evaluate its therapeutic potential.

The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study ...